Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion
The aim of this study was to evaluate a newly developed system for insulin delivery incorporating a multifunctional blood glucose meter and a remotely controlled insulin pump (ACCU-CHEK® Combo system) in established pump users with type 1 diabetes. The technology was assessed both from device perfor...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes science and technology 2010-11, Vol.4 (6), p.1400-1407 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1407 |
|---|---|
| container_issue | 6 |
| container_start_page | 1400 |
| container_title | Journal of diabetes science and technology |
| container_volume | 4 |
| creator | Kerr, David Hoogma, Roel P L M Buhr, Andreas Petersen, Bettina Storms, Fred E M G |
| description | The aim of this study was to evaluate a newly developed system for insulin delivery incorporating a multifunctional blood glucose meter and a remotely controlled insulin pump (ACCU-CHEK® Combo system) in established pump users with type 1 diabetes. The technology was assessed both from device performance and subject usability perspectives.
A multicenter, prospective, single group study was carried out in five centers in the Netherlands and four centers in the United Kingdom for more than 6 months. The study was divided into two phases: Phase 1 (4 weeks) for device validation purposes and phase 2 (22 weeks) to observe the impact of the system on metabolic control, patient satisfaction [using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)] and device safety.
Eighty subjects completed the planned study period. There were no unexpected device errors. Treatment satisfaction was high at baseline and further increased to study end (DTSQ change version: sum score, 10.6±7.2; scale score range, -18 to +18, p |
| doi_str_mv | 10.1177/193229681000400615 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3005051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21129336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3565-739f5b186c11ef50010107436e91a159dcc61bc115ebeb50499bb52d2430a3873</originalsourceid><addsrcrecordid>eNplUd1KwzAUDqK4OX0BLyQPYDWnaZrlRhhlOlHxxl2XpE1npE1G0wz2Uj6ET2bL5lDkwPn_vsM5B6FLIDcAnN-CoHEs0ikQQhJCUmBHaDwkIwqEH-_9oWOEzrz_IIQlU85P0SgGiAWl6Rj5l1B3ptC20y0Ovld6I-sgO-MsdhWeZdkyyhbzp69PnLlGuWssLTZ9-6qVnS6x3_pON7hyLS6c7YwNLnjsgypCJ60eAmN9qM2AqoLvec_RSSVrry_2doKW9_O3bBE9vz48ZrPnqKAsZRGnomIKpmkBoCtGCPTCE5pqARKYKIsiBdUXmVZaMZIIoRSLyzihRNIppxN0t-NdB9XocliylXW-bk0j223upMn_Vqx5z1duk9P-UoRBTxDvCIrWed_q6oAFkg8vyP-_oAdd_Z56gPzcnH4DnrqD-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kerr, David ; Hoogma, Roel P L M ; Buhr, Andreas ; Petersen, Bettina ; Storms, Fred E M G</creator><creatorcontrib>Kerr, David ; Hoogma, Roel P L M ; Buhr, Andreas ; Petersen, Bettina ; Storms, Fred E M G ; study investigators ; for the study investigators</creatorcontrib><description>The aim of this study was to evaluate a newly developed system for insulin delivery incorporating a multifunctional blood glucose meter and a remotely controlled insulin pump (ACCU-CHEK® Combo system) in established pump users with type 1 diabetes. The technology was assessed both from device performance and subject usability perspectives.
A multicenter, prospective, single group study was carried out in five centers in the Netherlands and four centers in the United Kingdom for more than 6 months. The study was divided into two phases: Phase 1 (4 weeks) for device validation purposes and phase 2 (22 weeks) to observe the impact of the system on metabolic control, patient satisfaction [using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)] and device safety.
Eighty subjects completed the planned study period. There were no unexpected device errors. Treatment satisfaction was high at baseline and further increased to study end (DTSQ change version: sum score, 10.6±7.2; scale score range, -18 to +18, p<0.0001). Hemoglobin A1c improved continuously over time, from 7.9% (±0.9%) to 7.7% (±0.8%) at month 3 (p<0.001) and 7.6% (±0.8%) at month 6 (p<0.0001). The frequency of severe hypoglycemia was 0.08 per patient years. There was no case of ketoacidosis.
The new system was evaluated by experienced continuous subcutaneous insulin infusion users as safe in daily practice and associated with favorable treatment satisfaction and a modest improvement in glycemic control.</description><identifier>ISSN: 1932-2968</identifier><identifier>EISSN: 1932-3107</identifier><identifier>DOI: 10.1177/193229681000400615</identifier><identifier>PMID: 21129336</identifier><language>eng</language><publisher>United States: Diabetes Technology Society</publisher><subject>Adult ; Biomarkers - blood ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Diabetes Mellitus, Type 1 - blood ; Diabetes Mellitus, Type 1 - drug therapy ; Equipment Design ; Equipment Safety ; Female ; Glycated Hemoglobin A - metabolism ; Humans ; Hypoglycemia - blood ; Hypoglycemia - chemically induced ; Hypoglycemia - prevention & control ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Infusions, Subcutaneous ; Insulin - administration & dosage ; Insulin - adverse effects ; Insulin Infusion Systems - adverse effects ; Male ; Middle Aged ; Monitoring, Ambulatory - instrumentation ; Netherlands ; Observer Variation ; Original ; Patient Satisfaction ; Predictive Value of Tests ; Prospective Studies ; Reproducibility of Results ; Surveys and Questionnaires ; Time Factors ; Treatment Outcome ; United Kingdom</subject><ispartof>Journal of diabetes science and technology, 2010-11, Vol.4 (6), p.1400-1407</ispartof><rights>2010 Diabetes Technology Society.</rights><rights>2010 Diabetes Technology Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3565-739f5b186c11ef50010107436e91a159dcc61bc115ebeb50499bb52d2430a3873</citedby><cites>FETCH-LOGICAL-c3565-739f5b186c11ef50010107436e91a159dcc61bc115ebeb50499bb52d2430a3873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005051/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005051/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21129336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kerr, David</creatorcontrib><creatorcontrib>Hoogma, Roel P L M</creatorcontrib><creatorcontrib>Buhr, Andreas</creatorcontrib><creatorcontrib>Petersen, Bettina</creatorcontrib><creatorcontrib>Storms, Fred E M G</creatorcontrib><creatorcontrib>study investigators</creatorcontrib><creatorcontrib>for the study investigators</creatorcontrib><title>Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion</title><title>Journal of diabetes science and technology</title><addtitle>J Diabetes Sci Technol</addtitle><description>The aim of this study was to evaluate a newly developed system for insulin delivery incorporating a multifunctional blood glucose meter and a remotely controlled insulin pump (ACCU-CHEK® Combo system) in established pump users with type 1 diabetes. The technology was assessed both from device performance and subject usability perspectives.
A multicenter, prospective, single group study was carried out in five centers in the Netherlands and four centers in the United Kingdom for more than 6 months. The study was divided into two phases: Phase 1 (4 weeks) for device validation purposes and phase 2 (22 weeks) to observe the impact of the system on metabolic control, patient satisfaction [using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)] and device safety.
Eighty subjects completed the planned study period. There were no unexpected device errors. Treatment satisfaction was high at baseline and further increased to study end (DTSQ change version: sum score, 10.6±7.2; scale score range, -18 to +18, p<0.0001). Hemoglobin A1c improved continuously over time, from 7.9% (±0.9%) to 7.7% (±0.8%) at month 3 (p<0.001) and 7.6% (±0.8%) at month 6 (p<0.0001). The frequency of severe hypoglycemia was 0.08 per patient years. There was no case of ketoacidosis.
The new system was evaluated by experienced continuous subcutaneous insulin infusion users as safe in daily practice and associated with favorable treatment satisfaction and a modest improvement in glycemic control.</description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Diabetes Mellitus, Type 1 - blood</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Equipment Design</subject><subject>Equipment Safety</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Hypoglycemia - blood</subject><subject>Hypoglycemia - chemically induced</subject><subject>Hypoglycemia - prevention & control</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Infusions, Subcutaneous</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - adverse effects</subject><subject>Insulin Infusion Systems - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monitoring, Ambulatory - instrumentation</subject><subject>Netherlands</subject><subject>Observer Variation</subject><subject>Original</subject><subject>Patient Satisfaction</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Reproducibility of Results</subject><subject>Surveys and Questionnaires</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>United Kingdom</subject><issn>1932-2968</issn><issn>1932-3107</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplUd1KwzAUDqK4OX0BLyQPYDWnaZrlRhhlOlHxxl2XpE1npE1G0wz2Uj6ET2bL5lDkwPn_vsM5B6FLIDcAnN-CoHEs0ikQQhJCUmBHaDwkIwqEH-_9oWOEzrz_IIQlU85P0SgGiAWl6Rj5l1B3ptC20y0Ovld6I-sgO-MsdhWeZdkyyhbzp69PnLlGuWssLTZ9-6qVnS6x3_pON7hyLS6c7YwNLnjsgypCJ60eAmN9qM2AqoLvec_RSSVrry_2doKW9_O3bBE9vz48ZrPnqKAsZRGnomIKpmkBoCtGCPTCE5pqARKYKIsiBdUXmVZaMZIIoRSLyzihRNIppxN0t-NdB9XocliylXW-bk0j223upMn_Vqx5z1duk9P-UoRBTxDvCIrWed_q6oAFkg8vyP-_oAdd_Z56gPzcnH4DnrqD-A</recordid><startdate>201011</startdate><enddate>201011</enddate><creator>Kerr, David</creator><creator>Hoogma, Roel P L M</creator><creator>Buhr, Andreas</creator><creator>Petersen, Bettina</creator><creator>Storms, Fred E M G</creator><general>Diabetes Technology Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>201011</creationdate><title>Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion</title><author>Kerr, David ; Hoogma, Roel P L M ; Buhr, Andreas ; Petersen, Bettina ; Storms, Fred E M G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3565-739f5b186c11ef50010107436e91a159dcc61bc115ebeb50499bb52d2430a3873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Diabetes Mellitus, Type 1 - blood</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Equipment Design</topic><topic>Equipment Safety</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Hypoglycemia - blood</topic><topic>Hypoglycemia - chemically induced</topic><topic>Hypoglycemia - prevention & control</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Infusions, Subcutaneous</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - adverse effects</topic><topic>Insulin Infusion Systems - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monitoring, Ambulatory - instrumentation</topic><topic>Netherlands</topic><topic>Observer Variation</topic><topic>Original</topic><topic>Patient Satisfaction</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Reproducibility of Results</topic><topic>Surveys and Questionnaires</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kerr, David</creatorcontrib><creatorcontrib>Hoogma, Roel P L M</creatorcontrib><creatorcontrib>Buhr, Andreas</creatorcontrib><creatorcontrib>Petersen, Bettina</creatorcontrib><creatorcontrib>Storms, Fred E M G</creatorcontrib><creatorcontrib>study investigators</creatorcontrib><creatorcontrib>for the study investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes science and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kerr, David</au><au>Hoogma, Roel P L M</au><au>Buhr, Andreas</au><au>Petersen, Bettina</au><au>Storms, Fred E M G</au><aucorp>study investigators</aucorp><aucorp>for the study investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion</atitle><jtitle>Journal of diabetes science and technology</jtitle><addtitle>J Diabetes Sci Technol</addtitle><date>2010-11</date><risdate>2010</risdate><volume>4</volume><issue>6</issue><spage>1400</spage><epage>1407</epage><pages>1400-1407</pages><issn>1932-2968</issn><eissn>1932-3107</eissn><abstract>The aim of this study was to evaluate a newly developed system for insulin delivery incorporating a multifunctional blood glucose meter and a remotely controlled insulin pump (ACCU-CHEK® Combo system) in established pump users with type 1 diabetes. The technology was assessed both from device performance and subject usability perspectives.
A multicenter, prospective, single group study was carried out in five centers in the Netherlands and four centers in the United Kingdom for more than 6 months. The study was divided into two phases: Phase 1 (4 weeks) for device validation purposes and phase 2 (22 weeks) to observe the impact of the system on metabolic control, patient satisfaction [using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)] and device safety.
Eighty subjects completed the planned study period. There were no unexpected device errors. Treatment satisfaction was high at baseline and further increased to study end (DTSQ change version: sum score, 10.6±7.2; scale score range, -18 to +18, p<0.0001). Hemoglobin A1c improved continuously over time, from 7.9% (±0.9%) to 7.7% (±0.8%) at month 3 (p<0.001) and 7.6% (±0.8%) at month 6 (p<0.0001). The frequency of severe hypoglycemia was 0.08 per patient years. There was no case of ketoacidosis.
The new system was evaluated by experienced continuous subcutaneous insulin infusion users as safe in daily practice and associated with favorable treatment satisfaction and a modest improvement in glycemic control.</abstract><cop>United States</cop><pub>Diabetes Technology Society</pub><pmid>21129336</pmid><doi>10.1177/193229681000400615</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-2968 |
| ispartof | Journal of diabetes science and technology, 2010-11, Vol.4 (6), p.1400-1407 |
| issn | 1932-2968 1932-3107 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3005051 |
| source | MEDLINE; SAGE Complete A-Z List; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Equipment Design Equipment Safety Female Glycated Hemoglobin A - metabolism Humans Hypoglycemia - blood Hypoglycemia - chemically induced Hypoglycemia - prevention & control Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Infusions, Subcutaneous Insulin - administration & dosage Insulin - adverse effects Insulin Infusion Systems - adverse effects Male Middle Aged Monitoring, Ambulatory - instrumentation Netherlands Observer Variation Original Patient Satisfaction Predictive Value of Tests Prospective Studies Reproducibility of Results Surveys and Questionnaires Time Factors Treatment Outcome United Kingdom |
| title | Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A56%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20user%20evaluation%20of%20ACCU-CHEK%C2%AE%20Combo,%20an%20integrated%20system%20for%20continuous%20subcutaneous%20insulin%20infusion&rft.jtitle=Journal%20of%20diabetes%20science%20and%20technology&rft.au=Kerr,%20David&rft.aucorp=study%20investigators&rft.date=2010-11&rft.volume=4&rft.issue=6&rft.spage=1400&rft.epage=1407&rft.pages=1400-1407&rft.issn=1932-2968&rft.eissn=1932-3107&rft_id=info:doi/10.1177/193229681000400615&rft_dat=%3Cpubmed_cross%3E21129336%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/21129336&rfr_iscdi=true |